Article Text

Download PDFPDF
Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions
  1. E Choy1,
  2. N Sattar2
  1. 1
    Sir Alfred Baring Garrod Clinical Trials Unit, Academic Department of Rheumatology, King’s College, London, UK
  2. 2
    BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Scotland, UK
  1. Naveed Sattar, Professor of Metabolic Medicine, Faculty of Medicine, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK; nsattar{at}


In severe untreated rheumatoid arthritis (RA), reductions in high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol and total cholesterol have been noted; this is in line with findings in other pathologies/conditions associated with inflammation or infection, such as sepsis, cancer, trauma or the postoperative period. Although the precise mechanisms remain to be established, cytokine-induced activation of the reticuloendothelial system is potentially critical to such changes. Consequently, dampening of inflammation in severe RA—as occurs with several biologics—may lead to increases, not only in high-density lipoprotein-cholesterol, but also with other lipid moieties, including total and low-density lipoprotein-cholesterol and, perhaps, triglycerides. This concept is consistent with findings following antitumour necrosis factor treatment and interleukin-6 receptor inhibition in patients with RA. At the same time, it is increasingly apparent that potent dampening of inflammation, however achieved, broadly reduces the risk of cardiovascular disease in RA. Therefore, changes in lipid profiles, particularly increases in cholesterol and triglycerides that occur with treatments for severe inflammation, may not represent increased cardiovascular risk as in the usual understanding of lipid-level elevations in individuals without significant inflammation. Rather, changes in lipid levels, in part or largely, may represent a predictable response to attenuation of inflammation. These observations are increasingly important clinically and should aid in the understanding and interpretation of lipid changes under inflammatory conditions, as well as in the context of potent anti-inflammatory interventions.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests: EC has provided consultancy through advisory boards and speakers bureaus for MSD, Pfizer, GSK, Abbott, Schering Plough, Wyeth, Merrimack Pharmaceutical, Chelsea Therapeutics, UCB Celltech, F. Hoffmann-La Roche, Pierre Fabre Medicament, Allergan and Jazz Pharmaceuticals. NS has received fees for lectures and consulting from F. Hoffmann-La Roche and Abbott, as well as from many companies marketing lipid-lowering therapies, both statins and non-statin agents.